Lymphoma, Non-Hodgkin: all 2,043 studies

Page 10 of 21. Open to participants first (309), then studies with results posted, then the rest; newest registration first within each.

• A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) CancerActive, not recruitingNCT06139406Phase 1
• A Safety Study of PF-08046045/SGN-35T in Adults With Advanced CancersTerminatedNCT06120504Phase 1
• LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin LymphomaActive, not recruitingNCT06090162Not applicable
• Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT06088654Phase 1/2
• Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)Active, not recruitingNCT06040320Phase 1/2
• Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's LymphomaWithdrawnNCT06005649Phase 1/2
• Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer SurvivorsActive, not recruitingNCT06002828
• Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin LymphomaTerminatedNCT05994157Phase 1
• TmCD19-IL18 in CD19+ CancersActive, not recruitingNCT05989204Phase 1
• Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS StudyCompletedNCT05972577Not applicable
• Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin LymphomasTerminatedNCT05965505Phase 1
• A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's LymphomaActive, not recruitingNCT05950165Phase 1/2
• Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell TherapyWithdrawnNCT05936229Phase 1/2
• Deciphering the Role of Circular RNAs in ALKpositive Anaplastic Large-cell LymphomaActive, not recruitingNCT05934045
• A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in ChinaCompletedNCT05896774Phase 1
• A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)Active, not recruitingNCT05885464Phase 1/2
• Cord Blood Transplant in Adults With Blood CancersActive, not recruitingNCT05884333Phase 2
• A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)TerminatedNCT05879744Phase 1
• Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)Active, not recruitingNCT05878184Phase 1
• A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)CompletedNCT05844956Phase 1/2
• A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-LymphomaActive, not recruitingNCT05840289
• A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell MalignanciesTerminatedNCT05828589Phase 1
• DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompletedNCT05824585Phase 1
• GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin LymphomaStatus unknownNCT05797948Not applicable
• Observational Study of People Living With HIV Treated With CD19-directed CAR T CellCompletedNCT05784415
• HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesWithdrawnNCT05740449Phase 1/2
• First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228Active, not recruitingNCT05737628Phase 1
• Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)TerminatedNCT05721222Phase 1/2
• A Rollover Study of CC-122Active, not recruitingNCT05688475Phase 1
• Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin LymphomaCompletedNCT05665725Phase 1
• ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell MalignanciesCompletedNCT05653271Phase 1
• A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHLActive, not recruitingNCT05627856Phase 1/2
• Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted TreatmentActive, not recruitingNCT05627245Phase 1
• Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT05621096Phase 1
• Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin LymphomaTerminatedNCT05618366Phase 1
• Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 TabletsActive, not recruitingNCT05618028Phase 1
• Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell MalignanciesTerminatedNCT05611853Phase 1/2
• A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and PharmacodynamicsTerminatedNCT05607199Phase 1
• First in Human, Dose Escalation, Dose Expansion Study of AUR105TerminatedNCT05605119Phase 1
• Improving Exercise Capacity With a Tailored Physical Activity InterventionActive, not recruitingNCT05595577Not applicable
• Living Conditions After Non-Hodgkin's Lymphoma in FranceCompletedNCT05583318
• A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)Active, not recruitingNCT05578976Phase 3
• A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell LymphomaActive, not recruitingNCT05574114Phase 1
• Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLLStatus unknownNCT05557903Phase 1
• Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical TrialActive, not recruitingNCT05556720Phase 3
• A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell TransplantActive, not recruitingNCT05540340Phase 1
• A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLLTerminatedNCT05515406Phase 1
• Study of Let-7a and miRNA-124 in Cases of Non-Hodgkin's Lymphoma and Acute LeukemiaStatus unknownNCT05477667Not applicable
• A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular LymphomaActive, not recruitingNCT05451810Phase 2
• The Effect of Decision Support System on Symptom Self-Management in Non-Hodgkin Lymphoma PatientsCompletedNCT05443165Not applicable
• A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell LymphomaWithdrawnNCT05431179Phase 3
• A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT05424822Phase 1
• Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's LymphomaCompletedNCT05422521Not applicable
• A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT05421663Phase 1/2
• Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at StanfordWithdrawnNCT05416554Not applicable
• Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell MalignanciesWithdrawnNCT05410041Phase 1
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular LymphomaActive, not recruitingNCT05409066Phase 3
• A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)TerminatedNCT05403450Phase 1
• Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in CancerSuspendedNCT05400122Phase 1
• Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin LymphomasActive, not recruitingNCT05400109Phase 1
• Study of PIT565 in Relapsed and/or Refractory B-cell MalignanciesActive, not recruitingNCT05397496Phase 1
• Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple MyelomaActive, not recruitingNCT05363800Phase 1
• Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLLTerminatedNCT05360238Phase 1/2
• Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B-NHL After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) TherapyStatus unknownNCT05349266Phase 1
• First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic MalignanciesTerminatedNCT05348889Phase 1/2
• Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and LymphomaActive, not recruitingNCT05346809Phase 2
• A Study of CNTY-101 in Participants With CD19-Positive B-Cell MalignanciesTerminatedNCT05336409Phase 1
• Study of 3D189 in Patients With Hematologic MalignanciesCompletedNCT05320809Phase 1
• GVM±R in Patients With Relapsed or Refractory Aggressive NHLActive, not recruitingNCT05299164Phase 1
• A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin LymphomaActive, not recruitingNCT05283720Phase 2
• Sepantronium Bromide for the Treatment of High-grade B-cell LymphomaActive, not recruitingNCT05263583Phase 2
• MargheRITA (Remote Intelligence for Therapeutic Adherence)CompletedNCT05260203Not applicable
• Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid TumorsCompletedNCT05225584Phase 1
• Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin LymphomaTerminatedNCT05221385Phase 1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaTerminatedNCT05219513Phase 1
• A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word ConditionsCompletedNCT05217914
• A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)Active, not recruitingNCT05210868Phase 1/2
• An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory LymphomaStatus unknownNCT05208853Early Phase 1
• A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell MalignanciesActive, not recruitingNCT05207670Phase 2
• Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of EpcoritamabActive, not recruitingNCT05206357Phase 1
• Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin LymphomaStatus unknownNCT05206071Not applicable
• Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS TrialCompletedNCT05205512Not applicable
• Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell LymphomaActive, not recruitingNCT05202782Phase 2
• Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid StudyStatus unknownNCT05191225Phase 4
• HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT05190068Phase 1
• Fitness Assessment in Young Adults Recovered From LymphomaCompletedNCT05188755Not applicable
• A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult ParticipantsCompletedNCT05176873Phase 1
• A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT05169515Phase 1
• Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin LymphomaStatus unknownNCT05164770Phase 3
• Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)Status unknownNCT05155839Phase 1
• Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLLTerminatedNCT05153330Phase 1
• Study of XL114 in Subjects With Non-Hodgkin's LymphomaTerminatedNCT05144347Phase 1
• A Study of BTX-1188 in Subjects With Advanced MalignanciesTerminatedNCT05144334Phase 1
• (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).WithdrawnNCT05134740Phase 1
• The BurnAlong Pilot Study for Adolescent and Young Adult Cancer SurvivorsCompletedNCT05131815Not applicable
• A Phase I Study of ZN-d5 in Chinese Subjects With Non-Hodgkin LymphomaTerminatedNCT05127811Phase 1
• Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse EventsCompletedNCT05123001
• PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell MalignanciesTerminatedNCT05107856Phase 1
• Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin LymphomaStatus unknownNCT05097443Phase 3
• CAR20.19.22 T-cells in Relapsed, Refractory B-cell MalignanciesTerminatedNCT05094206Phase 1

← Lymphoma, Non-Hodgkin overview